Co-Authors
This is a "connection" page, showing publications co-authored by JOSE ANTONIO KARAM and KANISHKA SIRCAR.
Connection Strength
2.168
-
Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urol Oncol. 2021 11; 39(11):790.e17-790.e23.
Score: 0.201
-
Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol. 2019 11; 32(11):1698-1707.
Score: 0.174
-
Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer. 2017 Dec 15; 123(24):4823-4831.
Score: 0.153
-
Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. Clin Cancer Res. 2017 Nov 01; 23(21):6686-6696.
Score: 0.152
-
The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. J Urol. 2016 Sep; 196(3):678-84.
Score: 0.139
-
Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urol Oncol. 2016 May; 34(5):237.e19-26.
Score: 0.137
-
Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas. J Pathol Clin Res. 2015 Oct; 1(4):212-24.
Score: 0.132
-
Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol. 2015 Sep; 28(9):1225-35.
Score: 0.132
-
Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol. 2015 Oct; 33(10):427.e17-23.
Score: 0.131
-
Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urol Oncol. 2015 Apr; 33(4):166.e21-9.
Score: 0.129
-
YIA24-001: Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial. J Natl Compr Canc Netw. 2024 Apr 05; 22(2.5).
Score: 0.061
-
A generative adversarial approach to facilitate archival-quality histopathologic diagnoses from frozen tissue sections. Lab Invest. 2022 05; 102(5):554-559.
Score: 0.052
-
Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clin Genitourin Cancer. 2021 12; 19(6):e401-e408.
Score: 0.051
-
Correction: Macrophage HIF-1a Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res. 2021 Jun 01; 27(11):3265.
Score: 0.050
-
Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers (Basel). 2021 Apr 30; 13(9).
Score: 0.050
-
Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol. 2021 02; 39(2):134.e9-134.e16.
Score: 0.048
-
Macrophage HIF-1a Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res. 2020 09 15; 26(18):4970-4982.
Score: 0.047
-
Integrated transcriptomic-genomic tool Texomer profiles cancer tissues. Nat Methods. 2019 05; 16(5):401-404.
Score: 0.043
-
Uc.416?+?A promotes epithelial-to-mesenchymal transition through miR-153 in renal cell carcinoma. BMC Cancer. 2018 Oct 04; 18(1):952.
Score: 0.041
-
Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol. 2017 09; 198(3):530-537.
Score: 0.037
-
Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer. 2017 06; 15(3):363-370.
Score: 0.037
-
Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017 12; 120(6):782-792.
Score: 0.037
-
Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. Eur Urol. 2016 08; 70(2):348-57.
Score: 0.035
-
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2016 05; 69(5):866-74.
Score: 0.034
-
Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 2016 May; 117(5):761-5.
Score: 0.033
-
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2015 Sep; 3(9):1017-29.
Score: 0.033